JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Ocular Therapeutix Inc

Geschlossen

BrancheGesundheitswesen

12.19 2.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

12.14

Max

12.24

Schlüsselkennzahlen

By Trading Economics

Einkommen

-16M

-64M

Verkäufe

-6.4M

11M

Gewinnspanne

-602.342

Angestellte

274

EBITDA

-20M

-64M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+42.83% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

510M

1.8B

Vorheriger Eröffnungskurs

9.67

Vorheriger Schlusskurs

12.19

Nachrichtenstimmung

By Acuity

50%

50%

145 / 375 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Ocular Therapeutix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Juli 2025, 17:53 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25. Juli 2025, 15:58 UTC

Ergebnisse
Wichtige Markttreiber

Aon Shares Rise After 2Q Earnings Beat

25. Juli 2025, 15:08 UTC

Wichtige Markttreiber

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25. Juli 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25. Juli 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25. Juli 2025, 20:40 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 20:10 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 19:56 UTC

Ergebnisse

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25. Juli 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25. Juli 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25. Juli 2025, 19:01 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Sale Could Fetch Around $1B, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH in Talks to Sell Marc Jacobs -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25. Juli 2025, 18:35 UTC

Akquisitionen, Fusionen, Übernahmen

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25. Juli 2025, 17:38 UTC

Wichtige Markttreiber

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25. Juli 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25. Juli 2025, 17:13 UTC

Ergebnisse

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25. Juli 2025, 16:46 UTC

Ergebnisse

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25. Juli 2025, 16:45 UTC

Ergebnisse

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25. Juli 2025, 16:27 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. Juli 2025, 16:02 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25. Juli 2025, 15:34 UTC

Ergebnisse

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25. Juli 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25. Juli 2025, 15:05 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25. Juli 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25. Juli 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25. Juli 2025, 14:36 UTC

Market Talk
Ergebnisse

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Peer-Vergleich

Kursveränderung

Ocular Therapeutix Inc Prognose

Kursziel

By TipRanks

42.83% Vorteil

12-Monats-Prognose

Durchschnitt 17.44 USD  42.83%

Hoch 22 USD

Tief 14 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ocular Therapeutix Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

10

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

6.97 / 7.62Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

145 / 375 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.